Head of Pharmaceutical Development, Reneo Pharma

With a diverse background in both large pharma and biotech companies, Helen leads the successful technical and strategic development of novel compounds, devices, and businesses.

She has proven track record in the successful development of innovative project strategies and their delivery to key milestones. A leader of global, multidisciplinary teams in CMC, diagnostics, clinical research, and across the R&D sphere.

Helen is the Head of Pharmaceutical Development at Reneo Pharma Ltd. She is also the founder and managing director of Project-ion Ltd, supporting the development of biotech and non-profit organizations.

Helen enjoyed a range of positions within Pfizer, Bristol-Myers Squibb, multiple start-up companies, and the University of Oxford, enabled by degrees in Chemical and Pharmaceutical Science and an MBA. She was Head of Pharmaceutical Development at Ziarco, which was acquired by Novartis in 2017.

She is a Faculty Fellow of the Royal Pharmaceutical Society, a Chartered Chemist, Chartered Scientist and a Fellow of the Royal Society of Chemistry.

Therapeutic areas of particular expertise include respiratory, infectious, and orphan diseases. Further interests include business strategy development, supporting emerging pharmaceutical scientist leaders, and patient and public involvement in research.


20 May 2021